Buspirone Daily Dosing Regimen
Start buspirone at 5 mg twice daily (10 mg/day total) and titrate up to a maximum of 20 mg three times daily (60 mg/day total), with the understanding that therapeutic effects require 1-4 weeks to manifest. 1
Initial Dosing and Titration
Begin with 5 mg twice daily (BID), which is the recommended starting dose per the American Academy of Family Physicians. 1
The maximum recommended dose is 60 mg/day, administered as 20 mg three times daily (TID). 1
Most clinical trials have used 30 mg/day as the standard therapeutic dose, administered either as 15 mg BID or 10 mg TID, with both regimens showing equivalent efficacy and safety. 2, 3
Doses up to 45 mg/day have been studied in patients with generalized anxiety disorder and coexisting mild depressive symptoms, showing superior efficacy to placebo. 4
Dosing Schedule Options
Two dosing schedules are equally effective:
15 mg twice daily (BID) – offers convenience and potentially better compliance 2, 3
10 mg three times daily (TID) – traditional dosing schedule 2, 3
The BID regimen showed a slightly higher incidence of palpitations (5% vs 1%) compared to TID, but otherwise had similar adverse event profiles. 2 The choice between BID and TID can be based on patient preference for convenience versus more frequent dosing.
Time to Therapeutic Effect
Critical timing considerations:
Initial anxiolytic effects begin at 1-2 weeks, unlike benzodiazepines which work immediately. 1
Full therapeutic effect requires 2-4 weeks of continuous treatment. 1
Patients must be counseled about this delayed onset to prevent premature discontinuation.
Pharmacokinetic Considerations
Administer with food – food increases both peak concentration (Cmax) and area under the curve (AUC) by 2-fold. 5
No dose accumulation occurs with chronic administration due to the short elimination half-life of approximately 2.5 hours. 5
The absolute bioavailability is only 4% due to extensive first-pass metabolism. 5
Special Populations
Hepatic or renal impairment:
- Buspirone is contraindicated in severe hepatic or renal impairment – plasma levels increase 15-fold in hepatic impairment and 2-fold in renal impairment, with doubled half-life in liver disease. 6, 5
Elderly patients:
No dose adjustment is required based on age alone, as pharmacokinetics are not affected by age. 6, 5
However, greater sensitivity in some older patients cannot be ruled out. 6
Pediatric patients:
Buspirone is not recommended for pediatric GAD – two placebo-controlled trials in 559 pediatric patients (ages 6-17) showed no significant differences from placebo at doses of 15-60 mg/day. 6
Despite lack of FDA approval for pediatric anxiety, case series suggest potential benefit in specific populations like high-functioning autism spectrum disorder (mean dose 41.61 mg/day) and Williams syndrome. 7, 8
Important Drug Interactions
Avoid or adjust for these interactions:
CYP3A4 inhibitors (verapamil, diltiazem, erythromycin, itraconazole) substantially increase buspirone levels. 5
Rifampin decreases buspirone levels almost 10-fold – avoid combination. 5
MAOIs are contraindicated with buspirone. 6
Cimetidine and alprazolam have negligible effects on buspirone levels. 5
Common Adverse Effects
Most frequent side effects (>5% incidence):
Dizziness (12%), nausea (8%), headache (6%), nervousness (5%), drowsiness (10%), and lightheadedness (3%). 6
Approximately 10% of patients discontinue due to adverse events, primarily CNS disturbances (3.4%) and GI disturbances (1.2%). 6
Clinical Pearls
Discontinue 48 hours before urine catecholamine testing – buspirone interferes with urinary metanephrine/catecholamine assays, causing false-positive results for pheochromocytoma. 6
Buspirone is most suitable for patients with mild to moderate agitation who can tolerate the delayed onset of action. 1
For treatment-resistant depression, bupropion augmentation is superior to buspirone augmentation when added to citalopram. 1